Cargando…

Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021

Background: Longitudinal surveys to monitor the seroprevalence are required to support efforts for assessment of the levels of endemic stability in certain countries. We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)-specific antibodies in the serum samples in 2011–2...

Descripción completa

Detalles Bibliográficos
Autores principales: Gumanova, Nadezhda G., Gorshkov, Alexander U., Bogdanova, Natalya L., Korolev, Andrew I., Drapkina, Oxana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032149/
https://www.ncbi.nlm.nih.gov/pubmed/35455330
http://dx.doi.org/10.3390/vaccines10040581
_version_ 1784692569982107648
author Gumanova, Nadezhda G.
Gorshkov, Alexander U.
Bogdanova, Natalya L.
Korolev, Andrew I.
Drapkina, Oxana M.
author_facet Gumanova, Nadezhda G.
Gorshkov, Alexander U.
Bogdanova, Natalya L.
Korolev, Andrew I.
Drapkina, Oxana M.
author_sort Gumanova, Nadezhda G.
collection PubMed
description Background: Longitudinal surveys to monitor the seroprevalence are required to support efforts for assessment of the levels of endemic stability in certain countries. We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)-specific antibodies in the serum samples in 2011–2021, including a cohort study of 2019–2021, to evaluate the vaccination and anti-IgG-SARS-CoV-2–S1 RBD-positive statuses to assess the resistance and severity of COVID-19. Materials and Methods: Anti-SARS-CoV-2-S1 RBD-specific antibodies were assayed in the serum samples (N = 565) randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region. Among them there were the participants (N = 310) recruited in 2019–2021 with an endpoint of 30 October 2021 when these participants were interviewed over phone with relevant questionnaire. Results: Obtained data indicated a percentage of 3–6% of SARS-CoV-2-S1 RBD-specific antibodies detected in participants recruited in 2011–2019. The percentage of SARS-CoV-2-S1 RBD-specific antibodies was increased to 16.5% in 2020 and to 46% in 2021. The vaccination rate of 238 respondents of this cohort was 58% from August 2020 to October 2021. In total, 12% of respondents were hospitalized. The morbidity rate in the subgroup of anti-SARS-CoV-2-S1 RBD-positive respondents was 5.4-fold higher than that in the subgroup of vaccinated respondents. Conclusions: A small percentage of SARS-CoV-2-S1 RBD-specific antibodies detected in 2011–2019 indicated possible spreading of coronaviruses during the pre-pandemic period. Collective immunity in Moscow and the Moscow region was able to reach 69% from August 2020 to October 2021 if this rate is added to the rate of not vaccinated SARS-CoV-2-S1 RBD-positive subjects.
format Online
Article
Text
id pubmed-9032149
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90321492022-04-23 Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021 Gumanova, Nadezhda G. Gorshkov, Alexander U. Bogdanova, Natalya L. Korolev, Andrew I. Drapkina, Oxana M. Vaccines (Basel) Article Background: Longitudinal surveys to monitor the seroprevalence are required to support efforts for assessment of the levels of endemic stability in certain countries. We investigated seroprevalence of anti-SARS-CoV-2-S1 receptor-binding domain (RBD)-specific antibodies in the serum samples in 2011–2021, including a cohort study of 2019–2021, to evaluate the vaccination and anti-IgG-SARS-CoV-2–S1 RBD-positive statuses to assess the resistance and severity of COVID-19. Materials and Methods: Anti-SARS-CoV-2-S1 RBD-specific antibodies were assayed in the serum samples (N = 565) randomly selected from various cohorts previously recruited from 2011 to 2021 from the city of Moscow and Moscow Region. Among them there were the participants (N = 310) recruited in 2019–2021 with an endpoint of 30 October 2021 when these participants were interviewed over phone with relevant questionnaire. Results: Obtained data indicated a percentage of 3–6% of SARS-CoV-2-S1 RBD-specific antibodies detected in participants recruited in 2011–2019. The percentage of SARS-CoV-2-S1 RBD-specific antibodies was increased to 16.5% in 2020 and to 46% in 2021. The vaccination rate of 238 respondents of this cohort was 58% from August 2020 to October 2021. In total, 12% of respondents were hospitalized. The morbidity rate in the subgroup of anti-SARS-CoV-2-S1 RBD-positive respondents was 5.4-fold higher than that in the subgroup of vaccinated respondents. Conclusions: A small percentage of SARS-CoV-2-S1 RBD-specific antibodies detected in 2011–2019 indicated possible spreading of coronaviruses during the pre-pandemic period. Collective immunity in Moscow and the Moscow region was able to reach 69% from August 2020 to October 2021 if this rate is added to the rate of not vaccinated SARS-CoV-2-S1 RBD-positive subjects. MDPI 2022-04-10 /pmc/articles/PMC9032149/ /pubmed/35455330 http://dx.doi.org/10.3390/vaccines10040581 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gumanova, Nadezhda G.
Gorshkov, Alexander U.
Bogdanova, Natalya L.
Korolev, Andrew I.
Drapkina, Oxana M.
Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title_full Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title_fullStr Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title_full_unstemmed Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title_short Detection of Anti-SARS-CoV-2-S1 RBD-Specific Antibodies Prior to and during the Pandemic in 2011–2021 and COVID-19 Observational Study in 2019–2021
title_sort detection of anti-sars-cov-2-s1 rbd-specific antibodies prior to and during the pandemic in 2011–2021 and covid-19 observational study in 2019–2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032149/
https://www.ncbi.nlm.nih.gov/pubmed/35455330
http://dx.doi.org/10.3390/vaccines10040581
work_keys_str_mv AT gumanovanadezhdag detectionofantisarscov2s1rbdspecificantibodiespriortoandduringthepandemicin20112021andcovid19observationalstudyin20192021
AT gorshkovalexanderu detectionofantisarscov2s1rbdspecificantibodiespriortoandduringthepandemicin20112021andcovid19observationalstudyin20192021
AT bogdanovanatalyal detectionofantisarscov2s1rbdspecificantibodiespriortoandduringthepandemicin20112021andcovid19observationalstudyin20192021
AT korolevandrewi detectionofantisarscov2s1rbdspecificantibodiespriortoandduringthepandemicin20112021andcovid19observationalstudyin20192021
AT drapkinaoxanam detectionofantisarscov2s1rbdspecificantibodiespriortoandduringthepandemicin20112021andcovid19observationalstudyin20192021